Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model

Neoplasia

Volumn 13, Issue 8, 2011, Pages 716-725

  Doucette, Tiffany ^a   Rao, Ganesh ^a   Yang, Yuhui ^a   Gumin, Joy ^a   Shinojima, Naoki ^a   Nebiyou Bekele, B ^a   Qiao, Wei ^a   Zhang, Wei ^a   Lang, Frederick F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CAROTID ARTERY; CELL HOMING; CELL MIGRATION; CELLULAR DISTRIBUTION; FLUORESCENCE MICROSCOPY; FRONTAL LOBE; GLIOMA; IMMUNOCOMPETENCE; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ENGRAFTMENT;

EID: 80051516653     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101680     Document Type: Article

References (50)

1. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, et al. (2006). Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24, 2707-2714.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
3. Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, et al. (2003). Phase I trial of adenovirusmediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21, 2508-2518.
4. Ahmed AU, Alexiades NG, and Lesniak MS (2010). The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Curr Opin Mol Ther 12, 546-552.
5. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, and Andreeff M (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-ß delivery into tumors. Cancer Res 62, 3603-3608.
6. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, and Andreeff M (2004). Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96, 1593-1603.
7. Kosztowski T, Zaidi HA, and Quinones-Hinojosa A (2009). Applications of neural and mesenchymal stem cells in the treatment of gliomas. Expert Rev Anticancer Ther 9, 597-612.
8. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, and Marshak DR (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147.
9. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, and Horwitz E (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317.
10. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, et al. (2000). Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97, 12846-12851.
11. Ehtesham M, Kabos P, Gutierrez MA, Chung NH, Griffith TS, Black KL, and Yu JS (2002). Induction of glioblastoma apoptosis using neural stem cell- mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 62, 7170-7174.
12. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, and Yu JS (2002). The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 62, 5657-5663.
13. Bianco P, Riminucci M, Gronthos S, and Robey PG (2001). Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19, 180-192.
14. Caplan AI and Bruder SP (2001). Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med 7, 259-264.
15. Tocci A and Forte L (2003). Mesenchymal stem cell: use and perspectives. Hematol J 4, 92-96.
16. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, et al. (2005). Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65, 3307-3318.
17. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y, and Hamada H (2004). Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11, 1155-1164.
18. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, and Shah K (2009). Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 106, 4822-4827.
19. Cassiede P, Dennis JE, Ma F, and Caplan AI (1996). Osteochondrogenic potential of marrow mesenchymal progenitor cells exposed to TGF-beta 1 or PDGF-BB as assayed in vivo and in vitro. J Bone Miner Res 11, 1264-1273.
20. Cheng P, Gao ZQ, Liu YH, and Xue YX (2009). Platelet-derived growth factor BB promotes the migration of bone marrow-derived mesenchymal stem cells towards C6 glioma and up-regulates the expression of intracellular adhesion molecule-1. Neurosci Lett 451, 52-56.
21. Hata N, Shinojima N, Gumin J, Yong R, Marini F, Andreeff M, and Lang FF (2010). Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery 66, 144-156, discussion 156-157.
22. Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, and Lang FF (2009). Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 69, 8932-8940.
23. de Vries NA, Beijnen JH, and van Tellingen O (2009). High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treat Rev 35, 714-723.
24. Hu X and Holland EC (2005). Applications of mouse glioma models in preclinical trials. Mutat Res 576, 54-65.
25. Wakimoto H, Kesari S, Farrell CJ, Curry WT Jr., Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, et al. (2009). Human glioblastoma- derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69, 3472-3481.
26. Garber K (2006). Realistic rodents? Debate grows over new mouse models of cancer. J Natl Cancer Inst 98, 1176-1178.
27. Garber K (2009). From human to mouse and back: "tumorgraft" models surge in popularity. J Natl Cancer Inst 101, 6-8.
28. Burns TC, Verfaillie CM, and Low WC (2009). Stem cells for ischemic brain injury: a critical review. J Comp Neurol 515, 125-144.
29. Holland EC, Hively WP, DePinho RA, and Varmus HE (1998). A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12, 3675-3685.
30. Becher OJ and Holland EC (2006). Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 66, 3355-3358, discussion 3358-3359.
31. Holland EC, Li Y, Celestino J, Dai CK, Schaefer L, Sawaya RA, and Fuller GN (2000). Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. Am J Pathol 157, 1031-1037.
32. [Rao G, Pedone CA, Coffin CM, Holland EC, and Fults DW (2003). c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestinexpressing neural progenitors in mice. Neoplasia 5, 198-204.
33. Rao G, Pedone CA, Valle LD, Reiss K, Holland EC, and Fults DW (2004). Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 23, 6156-6162.
34. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, and Zhang W (2007). Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 104, 11736-11741.
35. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, and Holland E (2009). Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4, e7752.
36. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al. (2006). Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173.
37. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, and Holland EC (2009). PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226-235.
38. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, Hambardzumyan D, and Holland EC (2010). Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6, 141-152.
39. Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN, Qiao W, Sawaya R, Rao G, and Heimberger AB (2011). Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res 16, 5722-5733.
40. Binning MJ, Niazi T, Pedone CA, Lal B, Eberhart CG, Kim KJ, Laterra J, and Fults DW (2008). Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth. Cancer Res 68, 7838-7845.
41. [Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, and Holland EC (2005). mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7, 356-368.
42. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, and Prockop DJ (2004). Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103, 1662-1668.
43. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, and Holland EC (2001). PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15, 1913-1925.
44. Pittenger MF and Marshak DR (2001). Mesenchymal stem cells of human adult bone marrow. In Stem Cell Biology. DR Marshak, RL Gardner, and D Gottlieb (Eds). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. pp. 349-373.
45. Azizi SA, Stokes D, Augelli BJ, DiGirolamo C, and Prockop DJ (1998). Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats-similarities to astrocyte grafts. Proc Natl Acad Sci USA 95, 3908-3913.
46. Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L, and Zhu J (2009). Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Neurosurgery 65, 610-624, discussion 624.
47. Karp JM and Leng Teo GS (2009). Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4, 206-216.
48. Hong X, Miller C, Savant-Bhonsale S, and Kalkanis SN (2009). Antitumor treatment using interleukin-12-secreting marrow stromal cells in an invasive glioma model. Neurosurgery 64, 1139-1146, discussion 1146-1147.
49. Menon LG, Kelly K, Yang HW, Kim SK, Black PM, and Carroll RS (2009). Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 27, 2320-2330.
50. Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, and Lesniak MS (2008). Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26, 831-841.